1997
Late sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaNeoplasms, Second PrimaryRadiotherapyConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1994
Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy.
Longo D, Duffey P, Jaffe E, Raffeld M, Hubbard S, Fisher R, Wittes R, DeVita V, Young R. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. Journal Of Clinical Oncology 1994, 12: 2153-9. PMID: 7523607, DOI: 10.1200/jco.1994.12.10.2153.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyCyclophosphamideCytarabineDisease-Free SurvivalDoxorubicinEtoposideFemaleFollow-Up StudiesHumansLymphoma, Non-HodgkinMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazinePrognosisRemission InductionSurvival RateVincristineConceptsAdvanced stage diseaseProMACE-MOPPProMACE-CytaBOMBurkitt's lymphomaLocalized diseaseComplete responseInvolved-field radiation therapyCombination chemotherapy programsOverall survival rateEfficacy of cyclophosphamideTreatment of patientsHigh-grade lymphomaMedian followComplete remissionIntercurrent illnessAdult patientsChemotherapy programCombination chemotherapyOverall survivalAggressive lymphomaRadiation therapyPatientsLymphomaSurvival rateDisease
1992
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure.
Longo D, Duffey P, Young R, Hubbard S, Ihde D, Glatstein E, Phares J, Jaffe E, Urba W, DeVita V. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. Journal Of Clinical Oncology 1992, 10: 210-8. PMID: 1732422, DOI: 10.1200/jco.1992.10.2.210.Peer-Reviewed Original ResearchConceptsComplete response rateInitial remissionComplete remissionCombination chemotherapyHodgkin's diseaseSalvage therapyOverall survivalPeripheral blood stem cell supportResponse rateChemotherapy-induced complete remissionConventional-dose salvage therapyDate of relapseDurable second remissionsRemission 5 yearsSalvage combination chemotherapyShort initial remissionTreatment-related complicationsDisease-free survivalClinical prognostic factorsStem cell supportDuration of responsePrimary treatment regimenRelapse of patientsNational Cancer InstituteB symptoms
1991
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
Longo D, Duffey P, DeVita V, Wiernik P, Hubbard S, Phares J, Bastian A, Jaffe E, Young R. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP. Journal Of Clinical Oncology 1991, 9: 1409-20. PMID: 1712836, DOI: 10.1200/jco.1991.9.8.1409.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinDose-Response Relationship, DrugDoxorubicinFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaLomustineMaleMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission InductionStreptozocinSurvival RateVincristineConceptsAdvanced-stage Hodgkin's diseaseErythrocyte sedimentation rateDose intensityOverall survivalHodgkin's diseaseInitial erythrocyte sedimentation rateDisease-free survival ratesDisease-free survival curvesComplete response rateDisease-free survivalBetter overall survivalPoor prognostic factorSecondary acute leukemiaHigher platelet countsAssessable patientsPrognostic factorsPlatelet countAcute leukemiaTreatment outcomesMOPPPatientsResponse rateSurvival rateSurvival curvesDiseaseTreatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment.
Longo D, Russo A, Duffey P, Hubbard S, Glatstein E, Hill J, Jaffe E, Young R, DeVita V. Treatment of advanced-stage massive mediastinal Hodgkin's disease: the case for combined modality treatment. Journal Of Clinical Oncology 1991, 9: 227-35. PMID: 1988570, DOI: 10.1200/jco.1991.9.2.227.Peer-Reviewed Original ResearchConceptsMediastinal Hodgkin's diseaseDisease-free survivalComplete respondersModality treatmentHodgkin's diseaseNational Cancer InstituteComplete remissionRadiation therapyMantle radiation therapyStage IIB diseaseOverall survival differenceMOPP chemotherapyDurable remissionsIIB diseaseLate complicationsModality therapyOverall survivalComplete responseMediastinal massSubsequent therapyTumor mortalitySurvival differencesChest radiographsRetrospective analysisMaximal responseLong-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas
Fisher R, Longo D, DeVita V, Hubbard S, Miller T, Young R. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas. Annals Of Oncology 1991, 2: 33-35. PMID: 1710487, DOI: 10.1093/annonc/2.suppl_1.33.Peer-Reviewed Original ResearchConceptsDisease-free survivalProMACE-MOPPCR rateComplete remissionProMACE-CytaBOMHodgkin's lymphomaLong-term disease-free survivalLong-term disease-free survivorsSurvival curvesStage IIDisease-free survival curvesFirst-generation regimensThird-generation regimensPhase II studyDisease-free survivorsOverall survival curvesSouthwest Oncology GroupCooperative group settingHigh-grade NHLNational Cancer InstituteSame time pointsVs 53Aggressive NHLII studyOncology Group
1988
Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.
Surbone A, Longo D, DeVita V, Ihde D, Duffey P, Jaffe E, Solomon D, Hubbard S, Young R. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. Journal Of Clinical Oncology 1988, 6: 1832-7. PMID: 3199167, DOI: 10.1200/jco.1988.6.12.1832.Peer-Reviewed Original ResearchConceptsResidual abdominal massesClinical complete remissionAbdominal massAggressive lymphomaNational Cancer InstituteStable residual massComplete remissionCombination chemotherapyPathologic evaluationFull-dose combination chemotherapyResidual massSubsequent tumor necrosisViable lymphoma cellsEvidence of diseaseMonths of chemotherapyInitial tumor sizeRestaging laparotomyBulky diseaseNegative laparotomyDisseminated diseaseIntraabdominal diseaseMost patientsSurgical explorationResidual tumorResidual disease
1986
Twenty years of MOPP therapy for Hodgkin's disease.
Longo D, Young R, Wesley M, Hubbard S, Duffey P, Jaffe E, DeVita V. Twenty years of MOPP therapy for Hodgkin's disease. Journal Of Clinical Oncology 1986, 4: 1295-306. PMID: 3528400, DOI: 10.1200/jco.1986.4.9.1295.Peer-Reviewed Original ResearchConceptsEnd of treatmentHodgkin's diseaseComplete responseDisease patientsLymphocyte-depleted typeHodgkin's disease patientsHigher CR rateResults of treatmentMOPP therapyB symptomsIntercurrent illnessComplete remissionLonger remissionsCR rateHodgkin's lymphomaLonger survivalBiopsy specimensPatientsHigh dosesDiseaseRemissionLymphomaMore cyclesTreatmentLarge cells
1981
Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease
Schilsky R, Sherins R, Hubbard S, Wesley M, Young R, DeVita V. Long-term follow-up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. The American Journal Of Medicine 1981, 71: 552-556. PMID: 7282743, DOI: 10.1016/0002-9343(81)90205-9.Peer-Reviewed Original ResearchConceptsOvarian failureMOPP chemotherapyOvarian functionChemotherapy-induced ovarian failureAge 25Causes of amenorrheaCompletion of chemotherapyPercent of patientsLong-term followTime of evaluationTime of treatmentPersistent amenorrheaChemotherapy regimenOlder patientsMedian ageHodgkin's diseaseEstradiol levelsSerum gonadotropinPatientsAmenorrheaChemotherapyNormal childrenWomenDiseaseTreatmentThe consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture
Devita V. The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture. Cancer 1981, 47: 1-13. PMID: 6970069, DOI: 10.1002/1097-0142(19810101)47:1<1::aid-cncr2820470102>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseLong-term adverse consequencesPresence of symptomsNational Cancer InstituteMOPP programComplete remissionNodular sclerosisHistologic subtypeImmunosuppressive drugsNational mortalityEffective chemotherapyDrug treatmentCancer InstituteChemotherapyDiseaseCarcinogenic effectsAdverse effectsYoung populationMOPPAdverse consequencesImportant negative influenceRemissionSclerosisPatientsPrognosis
1977
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup.
Anderson T, Bender R, Fisher R, DeVita V, Chabner B, Berard C, Norton L, Young R. Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Journal Of The National Cancer Institute 1977, 61: 1057-66. PMID: 71205.Peer-Reviewed Original ResearchAdolescentAdultAgedBleomycinChildClinical Trials as TopicCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHumansLymphomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMechlorethamineMiddle AgedNeoplasm StagingPrednisoneProcarbazineRemission, SpontaneousTime FactorsVincristine
1976
Splenectomy in the chronic phase of chronic granulocytic leukemia. Effects in 32 patients.
Ihde D, Canellos G, Schwartz J, DeVita V. Splenectomy in the chronic phase of chronic granulocytic leukemia. Effects in 32 patients. Annals Of Internal Medicine 1976, 84: 17-21. PMID: 1060395, DOI: 10.7326/0003-4819-84-1-17.Peer-Reviewed Original ResearchConceptsChronic phase of chronic granulocytic leukemiaPhase of chronic granulocytic leukemiaChronic granulocytic leukemiaChronic phaseGranulocytic leukemiaPhiladelphia chromosome-positive patientsSurvival of patientsYear of diagnosisChronic phase of diseasePhase of diseaseMedian survivalProphylactic splenectomySplenectomy patientsPlatelet transfusionsElective splenectomyAdequate therapyMassive splenomegalyBlastic transformationEarly diseaseSplenectomyInfluence survivalPatientsStage of illnessLeukemiaSurvival
1975
Peritoneoscopy: a valuable staging tool in ovarian carcinoma.
Rosenoff S, Young R, Anderson T, Bagley C, Chabner B, Schein P, Hubbard S, DeVita V. Peritoneoscopy: a valuable staging tool in ovarian carcinoma. Annals Of Internal Medicine 1975, 83: 37-41. PMID: 125057, DOI: 10.7326/0003-4819-83-1-37.Peer-Reviewed Original ResearchConceptsOvarian carcinomaApparent clinical remissionValuable staging toolAdvanced diseaseClinical remissionExploratory laparotomyConsecutive patientsDiaphragmatic involvementPretreatment evaluationAbdominal radiotherapyTherapeutic failureLaboratory examinationsStaging toolPatientsCarcinomaLiver areaLaparotomyPeritoneoscopySecond lookPercentRemissionRadiotherapyRoentgenologicTherapyPelvis
1973
Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature.
Schein P, Kahn R, Gorden P, Wells S, Devita V. Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature. JAMA Internal Medicine 1973, 132: 555-61. PMID: 4355081, DOI: 10.1001/archinte.132.4.555.Peer-Reviewed Original ResearchMeSH KeywordsAdenoma, Islet CellAdultBlood GlucoseCarcinoid TumorChemical and Drug Induced Liver InjuryCreatinineFemaleFollow-Up StudiesHumansInsulinKidneyKidney Function TestsLiverLiver NeoplasmsMaleMiddle AgedNeoplasm MetastasisPancreatic NeoplasmsProinsulinProteinuriaRadionuclide ImagingRemission, SpontaneousStreptozocinTime FactorsTolbutamideCombined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.
DeVita V. Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal. National Cancer Institute Monograph 1973, 36: 373-9. PMID: 4744596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic AgentsBiopsyCarmustineChlorambucilCyclophosphamideDactinomycinDrug Therapy, CombinationEvaluation Studies as TopicFollow-Up StudiesHodgkin DiseaseHumansMechlorethamineMiddle AgedPrednisoneProcarbazineRemission, SpontaneousTime FactorsVinblastineVincristineCombination Chemotherapy and Survival in Advanced Hodgkin's Disease
Canellos G, Young R, Berard C, DeVita V. Combination Chemotherapy and Survival in Advanced Hodgkin's Disease. JAMA Internal Medicine 1973, 131: 388-390. PMID: 4569375, DOI: 10.1001/archinte.1973.00320090078008.Peer-Reviewed Original Research
1972
A decade of combination chemotherapy of advanced Hodgkin's disease
Devita V, Canellos G, Moxley J. A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer 1972, 30: 1495-1504. PMID: 4565815, DOI: 10.1002/1097-0142(197212)30:6<1495::aid-cncr2820300613>3.0.co;2-i.Peer-Reviewed Original ResearchConceptsAdvanced Hodgkin's diseaseComplete remission rateHodgkin's diseaseRemission rateRemission durationCombination chemotherapySingle agentLonger disease-free intervalDisease-free intervalAcute childhood leukemiaNew treatment programCombination of drugsComplete remissionComplete respondersCooperative trialsStage IIIChildhood leukemiaEffective drugsTreatment programTherapyUse of combinationsDiseasePilot studyFurther treatmentRemissionNonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive Therapy
Arseneau J, Sponzo R, Levin D, Schnipper L, Bonner H, Young R, Canellos G, Johnson R, DeVita V. Nonlymphomatous Malignant Tumors Complicating Hodgkin's Disease — Possible Association with Intensive Therapy. New England Journal Of Medicine 1972, 287: 1119-1122. PMID: 5082192, DOI: 10.1056/nejm197211302872204.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellCyclophosphamideDrug-Related Side Effects and Adverse ReactionsFemaleFibrosarcomaFollow-Up StudiesHead and Neck NeoplasmsHodgkin DiseaseHumansMaleMiddle AgedNeoplasm MetastasisNeoplasmsNeoplasms, Radiation-InducedNitrogen Mustard CompoundsPrednisoneProcarbazineRadiotherapyRemission, SpontaneousTime FactorsVincristineConceptsHodgkin's diseaseMalignant tumorsIntensive radiotherapyIntensive chemotherapyBiopsy-proven malignant tumorsTime of diagnosisSecond malignant tumorsRisk of developmentBasis of treatmentBasis of ageIntensive therapyCase recordsChemotherapyDiseasePatientsRadiotherapyTumorsGreater increaseSubgroupsRiskTherapyIncidenceDiagnosis
1971
Chemotherapeutic implications of staging in Hodgkin's disease.
DeVita V, Carbone P. Chemotherapeutic implications of staging in Hodgkin's disease. Cancer Research 1971, 31: 1838-44. PMID: 4941352.Peer-Reviewed Original Research
1970
Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma
Lowenbraun S, DeVita V, Serpick A. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer 1970, 25: 1018-1025. PMID: 4910254, DOI: 10.1002/1097-0142(197005)25:5<1018::aid-cncr2820250505>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsReticulum cell sarcomaComplete remissionPartial remissionRCS patientsCell sarcomaLSA patientsUnmaintained complete remissionOnset of therapyCombination of agentsGeneralized lymphosarcomaModerate myelosuppressionCombination chemotherapyRC patientsTherapy completionMean durationPatientsRemissionLymphosarcomaSarcomaVincristineDiseaseNitrogen mustardSurvivalSubstantial durationDuration